Evidence map›Paper›PMID 42417900›Full record

ReviewMolecular biology reports2026

BDNF and GSK-3β signaling in depression: molecular mechanisms underlying neural plasticity dysfunction.

Hayder M Al-Kuraishy, Shimaa A Abass, Hitham Alaa Mohammed Mahana, Osama Ashraf Elbanna, Ibrahiym Yasser Shahin, Abdelrahman Ali Radwan, Omar El-Sayed MohamedMohamed, AbdAlRhman Mohamad Lotfy Baktoot, Gaber El-Saber Batiha

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hayder M Al-KuraishyDepartment of Pharmacology, Toxicology and Medicine, Medical Faculty, College of Medicine, Al-Mustansiriyah University, PO Box 14132, Baghdad, Iraq.
Shimaa A AbassDepartment of Biochemistry, Faculty of Pharmacy, Kaferelsheikh University, Kaferelsheikh, Egypt. shimaa_abass@pharm.kfs.edu.eg.ORCID http://orcid.org/0000-0002-0695-2251
Hitham Alaa Mohammed MahanaFaculty of Veterinary Medicine, Damanhour University, AlBeheira, Damanhour, 22511, Egypt.
Osama Ashraf ElbannaFaculty of Veterinary Medicine, Damanhour University, AlBeheira, Damanhour, 22511, Egypt.
Ibrahiym Yasser ShahinFaculty of Veterinary Medicine, Damanhour University, AlBeheira, Damanhour, 22511, Egypt.
Abdelrahman Ali RadwanFaculty of Veterinary Medicine, Damanhour University, AlBeheira, Damanhour, 22511, Egypt.
Omar El-Sayed MohamedMohamedFaculty of Veterinary Medicine, Damanhour University, AlBeheira, Damanhour, 22511, Egypt.
AbdAlRhman Mohamad Lotfy BaktootFaculty of Veterinary Medicine, Damanhour University, AlBeheira, Damanhour, 22511, Egypt.
Gaber El-Saber BatihaDepartment of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, AlBeheira, Damanhour, 22511, Egypt. dr_gaber_batiha@vetmed.dmu.edu.eg.ORCID http://orcid.org/0000-0002-7817-425X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Depression, a complicated psychiatric condition, is characterized by persistent low mood, disrupted emotional regulation, and cognitive impairment. Attenuated brain-derived neurotrophic factor (BDNF) and dysregulated glycogen synthase kinase-3 beta (GSK-3β) activity promote synaptic deterioration, oxidative imbalance, neuroinflammatory responses, and hippocampal dysfunction, hallmark features of depressive pathology. This review provides an overview of current preclinical and clinical findings explaining the independent and interactive roles of BDNF and GSK-3β in depression. It further illustrates emerging therapeutic approaches targeting this axis, such as metformin, famotidine, tideglusib, lithium, and ketamine. Collectively, the altered crosstalk between BDNF and GSK-3β contributes to the impaired neuroplasticity observed in depression, suggesting that this signaling axis is a promising therapeutic target.

Indexed as

Brain-Derived Neurotrophic FactorDepressionGlycogen Synthase Kinase 3 betaNeuronal PlasticityAnimalsHippocampusHumansSignal TransductionBDNF protein, humanBrain-Derived Neurotrophic FactorGlycogen Synthase Kinase 3 betaBDNFDepressionFamotidineGSK-3βKetamineLithiumMetforminTideglusib

Identifiers

PMID42417900

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.